In turn, inhibition of pro-fibrotic TGF-β1 signaling [123] and preservation of Cx43 via the prevention/attenuation of inflammation and oxidative stress appear to be a promising therapeutic strategy in PAH, as it is in HTN [19,20]. This evidence concerns the gene GJA1 and hypertensive disorder.